Create AI tools to monitor diseases such as MS

Mr Samuel Klistorner

The University of Sydney

August 2022

specialisation: Neurobiology

focus area: Better treatments

funding type: Scholarship

project type: Investigator Led Research

Summary

Recent evidence suggests that in addition to acute damage caused by lesions (spots of active inflammation in the brain and spinal cord), many people living with MS also display chronic inflammation around long-standing lesions (called slow-burning inflammation). Mr Klistorner and his team have shown that slow-burning inflammation (measured by MRI as an expansion of chronic lesions) is the most significant contributor to disease progression in people living with MS who are treated.  

Their recent study has revealed that this process of lesion expansion is initiated by the loss of myelin around chronic lesions. They have also demonstrated that the degree of lesion expansion depends on the distance from the ventricles, a structure in the middle of the brain filled with cerebral-spinal fluid, and is strongly associated with the size of the network of small vessels inside the ventricles (choroid plexus), which is likely to play a very important role in sustaining chronic inflammation in MS.  

The team are now investigating the relationship between plexus enlargement and inflammation around chronic lesions by examining people at the earliest stage of MS. In addition, they also plan to investigate potential effects of myelin repair therapies in preventing damage of brain tissue around chronic lesions. If confirmed, this will suggest that people living with MS displaying a significant degree of activity at the rim of chronic lesions may benefit from therapies that repair myelin. Based on the outcomes, the team will then develop an artificial intelligence (AI)-based model to assist in modelling lesion activity in a fast and semi-automated manner. 

Progress

The key discovery of Mr Klistorner’s research has been about chronic lesion expansion, which is the slow-burning inflammation that occurs around long-standing lesions. This is now understood to vary greatly between individuals and to progress over a long time. This insight could revolutionise how we assess and treat chronic lesion expansion, possibly leading to more personalised treatment strategies and becoming a focus for future clinical trials. 

In this project, chronic lesion expansion was also found to be closely linked to increased brain volume loss (atrophy), underscoring the importance of early and targeted treatment. 

publications

  • Klistorner, S., Barnett, M. H., Wang, C., Parratt, J., Yiannikas, C., & Klistorner, A. (2024). Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients. Multiple Sclerosis Journal, 13524585241228423. 
  • Klistorner, S., Barnett, M. H., Parratt, J., Yiannikas, C., & Klistorner, A. (2023). Short-term surrogate biomarkers of chronic lesion expansion. medRxiv, 2023-04. 
  • Klistorner, S., Barnett, M., Parratt, J., Yiannikas, C., & Klistorner, A. (2023). Evolution of Chronic Lesion Tissue in RRMS patients: An association with disease progression. medRxiv, 2023-12. 

Updated 31 March 2024 

lead investigator

total funding

$105,000

start year

2022

duration

3 years

STATUS

Current project

Stages of the research process

Fundamental laboratory Research

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline

10+ years

Translational Research

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline

5+ years

Clinical Studies and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline

3+ years

Read More
DR VIVIEN LI

Newsletter subscription

  • Enter your details

Create AI tools to monitor diseases such as MS